ライフサイエンスコーパス: mitral valve

1 s on the basis of valve position (aortic vs. mitral valve).

2 f a single clip at the A2-P2 segments of the mitral valve.

3 enerative process in the fibrous base of the mitral valve.

4 ed immediately after release obstructing the mitral valve.

5 sophageal echocardiography evaluation of the mitral valve.

6 ed myxomatous changes in the leaflets of the mitral valve.

7 ct through rotating reversal flow around the mitral valve.

8 phied septum and the anterior leaflet of the mitral valve.

9 in 11 myxomatous and 11 nonmyxomatous human mitral valves.

10 heter valve leaflets, 39%; stent frame, 17%; mitral valve, 21%).

11 Mitral valve abnormalities were not part of modern patho

12 itral ViV and ViR were compared according to Mitral Valve Academic Research Consortium criteria.

13 success 30 days after implantation using the Mitral Valve Academic Research Consortium definitions.

14 The Mitral Valve Academic Research Consortium is a collabora

15 the hypothesis that ischemic milieu modifies mitral valve adaptation.

16 relation of the 3-dimensional morphology of mitral valve and degree of mitral regurgitation (MR) in

17 t of cardiac development but, along with the mitral valve and trabeculae, their developmental traject

18 Restrictive mitral valve annuloplasty (RMA) for secondary mitral reg

19 two scales (nanometer and micrometer), using mitral valve anterior leaflet (MVAL) tissues as the repr

20 further in the structure and function of the mitral valve apparatus after TAVR.

21 heter aortic valve replacement (TAVR) on the mitral valve apparatus and factors influencing the reduc

22 The 3-dimensional geometry of mitral valve apparatus was measured with dedicated quant

23 oportional to their regression coefficients: mitral valve area </=1 cm(2) (2), maximum leaflets displ

24 Quantification of the mitral valve area (MVA) is important to guide percutaneo

25 that experimental tethering alone increases mitral valve area in association with endothelial-to-mes

26 adding prognostic value to clinical data and mitral valve area.

27 Detailed mitral valve assessment is likely to assume increasing i

28 in the 1990s structural abnormalities of the mitral valve became appreciated as contributing to SAM p

29 r descending coronary artery calcifications, mitral valve calcifications, descending aorta calcificat

30 ds, and outcomes of transcatheter aortic and mitral valve catheter-based valve procedures in the Unit

31 in those who received mechanical prosthetic mitral valves compared with those who received bioprosth

32 othesized that percutaneous plication of the mitral valve could reduce left ventricular outflow tract

33 Pathological processes underlying myxomatous mitral valve degeneration (MMVD) remain poorly understoo

34 Understanding the role of DCHS1 in mitral valve development and MVP pathogenesis holds pote

35 The mitral valve device reduced MR to </=2+ in 86% of patien

36 The percutaneous mitral valve device significantly reduced MR, improved c

37 Mean mitral valve diameter z score was lower (P<0.001) and th

38 with increased repair rates of degenerative mitral valve disease (adjusted odds ratio [OR]: 1.13 for

39 Forty-nine patients with degenerative mitral valve disease classified as FED (n=31) and DMD (n

40 eration (DMD) are phenotypes of degenerative mitral valve disease defined morphologically.

41 The field of mitral valve disease diagnosis and management is rapidly

42 ial tissues from the patients with rheumatic mitral valve disease in either sinus rhythm or persisten

43 he value of robotically assisted surgery for mitral valve disease is questioned because the high cost

44 ower the incidence of clinically significant mitral valve disease requires further study.

45 also develop aortic root aneurism and aorto-mitral valve disease that can be fatal depending on the

46 creased incidence of cardiovascular disease, mitral valve disease, arrhythmias, and mortality.

47 t outcomes in patients with heart failure or mitral valve disease, but their impact on outcomes in pa

48 AC, a risk factor for clinically significant mitral valve disease, suggesting a causal association.

49 ntional surgical approaches for degenerative mitral valve disease.

50 n selected patients with combined aortic and mitral valve disease.

51 o promote the development of AF in rheumatic mitral valve disease.

52 prove outcomes in patients with degenerative mitral valve disease.

53 sociation between KCN and allergic rhinitis, mitral valve disorder, aortic aneurysm, or depression (P

54 The impact of reduced IPMD shortening on mitral valve (dys)function was confirmed in swine and in

55 hyperlipidemia presented with no symptoms of mitral valve dysfunction and had no abnormalities on phy

56 Coming to a conclusion, bearing in mind no mitral valve dysfunction at that time, patient was offer

57 -risk patients treated with the percutaneous mitral valve edge-to-edge repair.

58 emiautomatically placed in the region of the mitral valve, factor analysis, and a hybrid method that

59 ase category, younger age, and morphological mitral valve features were risk factors for an unfavorab

60 bryos had increased crypt presence, abnormal mitral valve formation and alterations in the compaction

61 remodeling and more effectively restored the mitral valve geometric configuration in ischemic MR, whi

62 ing in the interpapillary muscle distance on mitral valve geometry and function in ischemic heart dis

63 om diastole to systole, and adversely affect mitral valve geometry and tethering.

64 NIMR creation altered mitral valve geometry by decreasing mitral annular nonpl

65 contraction, lateral shortening of the IPMD, mitral valve geometry, and severity of mitral regurgitat

66 Mean mitral valve gradients were similar between groups (6.4

67 or myxoid degeneration, billowing or floppy mitral valve) have appeared, 2 virtually constant histol

68 mpared with those who received bioprosthetic mitral valves; however, the incidence of reoperation was

69 cribe the first-in-man series of transapical mitral valve implantation for mitral regurgitation with

70 Transapical transcatheter mitral valve implantation is technically feasible and ca

71 Transcatheter mitral valve implantation may be a better therapeutic op

72 Transcatheter mitral valve implantation may become an important treatm

73 studies were conducted with the transapical mitral valve implantation of the Tiara system.

74 cally appropriate to determine transcatheter mitral valve implantation size and eligibility.

75 f the D-shaped MA to determine transcatheter mitral valve implantation size.

76 rgitation being considered for transcatheter mitral valve implantation who had undergone cardiac CT a

77 e of mechanical prosthetic and bioprosthetic mitral valves in patients aged 50 to 69 years matched by

78 features of operatively excised portions of mitral valves in patients with mitral valve prolapse (MV

79 ents who underwent mitral valve-in-valve and mitral valve-in-ring procedures were high risk, with an

80 The 349 patients who underwent mitral valve-in-valve and mitral valve-in-ring procedure

81 Transcatheter transapical mitral valve-in-valve implantation for dysfunctional bio

82 n zebrafish, cultured cells and, notably, in mitral valve interstitial cells (MVICs) obtained during

83 In vitro treatment of mitral valve interstitial cells with TGF-beta2 increased

84 The end point was either mitral valve intervention or death.

85 Staphylococcus aureus as a cause (HR 2.47), mitral valve involvement (HR 1.29), and anticoagulant th

86 ing prostheses specifically designed for the mitral valve is warranted.

87 ombination with 3 other parameters: anterior mitral valve leaflet elongation (beta=2.1; 95% CI, 1.7-3

88 of crypts (particularly multiple), anterior mitral valve leaflet elongation, abnormal trabeculae, an

89 ickness, morphology, left atrial volume, and mitral valve leaflet lengths (all P=non-significant).

90 Each underwent percutaneous mitral valve leaflet plication to reduce systolic anteri

91 fts (28% versus 8%; P=0.02), longer anterior mitral valve leaflets (23.5+/-3.0 versus 19.7+/-3.1 mm;

92 onship of left ventricular (LV) flow and the mitral valve leaflets (MVL) on 3-chamber vector flow map

93 oint of a line connecting the origins of the mitral valve leaflets at end systole and end diastole.

94 ium, biatrial enlargement, thickening of the mitral valve leaflets, and interatrial septum and mild p

95 er vector flow mapping frames, and performed mitral valve measurements on 2-dimensional frames in pat

96 n swine and in a physiological computational mitral valve model.

97 Mitral valve morphology was assessed by using both the c

98 omyopathy (HCM) and mild septal hypertrophy, mitral valve (MV) abnormalities may play an important ro

99 al septal hypertrophy, we sought to identify mitral valve (MV) and papillary muscle (PM) abnormalitie

100 The acute effect of MitraClip procedure on mitral valve (MV) annular geometry and its relation to f

101 Concerning mitral valve (MV) annular geometry, we found significant

102 A paucity of data exists on mitral valve (MV) deformation during the cardiac cycle i

103 Degenerative mitral valve (MV) disease is a common cause of severe mi

104 roups based on cardiovascular comorbidities: mitral valve (MV) disease without coronary artery diseas

105 y-three patients (20%) underwent concomitant mitral valve (MV) intervention (repair, n=29; replacemen

106 ever, LV size is an important determinant of mitral valve (MV) leaflet tethering before and after rep

107 Conventional mitral valve (MV) operations allow direct anatomic asses

108 R, due to underlying degenerative/structural mitral valve (MV) pathology, and secondary (functional)

109 Mitral valve (MV) repair is preferred over replacement i

110 ical outcomes and durability of percutaneous mitral valve (MV) repair with the MitraClip device compa

111 Transcatheter mitral valve (MV) repair with the MitraClip received app

112 For patients undergoing mitral valve (MV) repair, the indications for and result

113 Incidence and outcome of mitral valve (MV) surgery are unknown in patients with h

114 At 7.1 +/- 2.0 years, 86% had mitral valve (MV) surgery.

115 ume with hospital performance for aortic and mitral valve (MV) surgical procedures.

116 e is an increasing interest in transcatheter mitral valve (MV) treatment.

117 Mitral valves (MVs) are larger in such patients but fibr

118 ts the following manifestations: a prolapsed mitral valve, myopia, aortic root enlargement, and skele

119 ence between peak twisting and untwisting at mitral valve opening (%untwMVO) using speckle-tracking e

120 nction and maximum left atrium volume before mitral valve opening, and as such contains no added info

121 p) or no ablation (control group) during the mitral-valve operation.

122 th degenerative mitral disease who underwent mitral valve operations between 2002 and 2013.

123 Percutaneous closure of prosthetic mitral valve paravalvular leak (PVL) has emerged as an a

124 Advanced age and complex mitral valve pathologies increased the risk of late recu

125 Compared with patients with normal mitral valves, patients with bileaflet MVP: 1) were over

126 Precise definition of the mitral valve plane (VP) during segmentation of the left

127 This is a report of percutaneous mitral valve plication as a primary therapy in the manag

128 the potential effectiveness of percutaneous mitral valve plication as a therapy for patients with sy

129 nitial experience suggests that percutaneous mitral valve plication may be effective for symptom reli

130 Other concomitant operations included mitral valve procedure (11%), aortic valve procedure (9%

131 s study was to investigate the prevalence of mitral valve prolapse (MVP) and its association with ven

132 Knowledge of mitral valve prolapse (MVP) inheritance is based on pedi

133 Mitral valve prolapse (MVP) is a common cardiac valve di

134 Nonsyndromic mitral valve prolapse (MVP) is a common degenerative car

135 Although the vast majority of mitral valve prolapse (MVP) is benign, a small subset of

136 Arrhythmic mitral valve prolapse (MVP) is characterized by myxomato

137 Mitral valve prolapse (MVP) may present with ventricular

138 Longitudinal studies of mitral valve prolapse (MVP) progression among unselected

139 d portions of mitral valves in patients with mitral valve prolapse (MVP).

140 an syndrome include aortic root dilation and mitral valve prolapse (MVP).

141 We report a strong association between mitral valve prolapse and viridans group streptococcal I

142 Though most mitral valve prolapse are asymptomatic those that cause

143 Mitral valve prolapse is a common valvular abnormality b

144 disease valves will help relieve symptomatic mitral valve prolapse patients.

145 07-0.23), 0.12 (95% CI, 0.04-0.20) excluding mitral valve prolapse, and 0.44 (95% CI, 0.15-0.73) for

146 higher rates of scoliosis, pectus excavatum, mitral valve prolapse, and mutations in the CFTR gene.

147 e and degree of mitral regurgitation (MR) in mitral valve prolapse.

148 ay be important in the pathogenesis of MR in mitral valve prolapse.

149 levance when referring patients with complex mitral valve prolapse.

150 primary mitral regurgitation (MR) caused by mitral valve prolapse.

151 er, transapical delivery of a self-expanding mitral valve prosthesis and were examined in a prospecti

152 method and by two 3D quantification methods (mitral valve quantification software and 3D quantificati

153 edian MVAs by the pressure half-time method, mitral valve quantification software, and 3D quantificat

154 MA was developed using Philips Q-Laboratory mitral valve quantification software.

155 n of TMVR in lower-risk patients with severe mitral valve regurgitation (Evaluation of the Safety and

156 Secondary mitral valve regurgitation (MR) remains a challenging pr

157 s to the development of clinically important mitral valve regurgitation and mitral valve stenosis.

158 Atrial dilatation, mitral valve regurgitation, myocyte hypertrophy, and atr

159 MVP and suggests new mechanisms involved in mitral valve regurgitation, the most common indication f

160 ng transition essential for proper embryonic mitral valve remodeling.

161 luded coronary artery bypass grafting (13%), mitral valve repair (7%), and partial/complete arch repl

162 Surgical mitral valve repair (SMVR) remains the gold standard for

163 The use of transcatheter mitral valve repair (TMVR) has gained widespread accepta

164 However, the results with transcatheter mitral valve repair (TMVR) in prohibitive-risk DMR patie

165 Transcatheter mitral valve repair (TMVR) is a treatment option in pati

166 e devices currently available, transcatheter mitral valve repair (TMVr) remains challenging in comple

167 al regurgitation (MR) following degenerative mitral valve repair are poorly understood.

168 to evaluate renal function before and after mitral valve repair by the MitraClip device.

169 w likelihood of MR recurrence, regardless of mitral valve repair complexity.

170 dge-to-edge technique using the percutaneous mitral valve repair device in an ex vivo pulsatile model

171 commercially treated with this percutaneous mitral valve repair device were analyzed.

172 etween 1991 and 2010, patients who underwent mitral valve repair for primary mitral regurgitation wer

173 After mitral valve repair for primary mitral regurgitation, th

174 h a mean (SD) age of 57 (11) years underwent mitral valve repair for regurgitation from posterior lea

175 98.8% complete follow-up) underwent robotic mitral valve repair for severe nonischemic degenerative

176 the commercial experience with transcatheter mitral valve repair for the treatment of mitral regurgit

177 predict postoperative LVD and outcome after mitral valve repair in patients with primary mitral regu

178 In expert centers, mitral valve repair is achieved at low risk and with exc

179 In addition, transcatheter mitral valve repair is also routinely used in high surgi

180 ted that recurrent MR following degenerative mitral valve repair is associated with adverse left vent

181 elderly patients with mitral regurgitation, mitral valve repair is associated with superior early an

182 gs demonstrate that commercial transcatheter mitral valve repair is being performed in the United Sta

183 Mitral valve repair is favoured over replacement wheneve

184 ural costs, robotically assisted surgery for mitral valve repair offers the clinical benefit of least

185 nterval, 0.51-0.62; P<0.0001), and CABG plus mitral valve repair or replacement (adjusted hazard rati

186 In these cases, concomitant mitral valve repair or replacement is usually performed

187 artery bypass grafting (CABG), or CABG plus mitral valve repair or replacement.

188 ry intervention=26%, CABG=33%, and CABG plus mitral valve repair or replacement=5%.

189 uence of surgeon case volume on degenerative mitral valve repair rates and outcomes.

190 nnual mitral volumes of >50 and degenerative mitral valve repair rates of >70%, compared with surgeon

191 Degenerative mitral valve repair rates remain highly variable, despit

192 e interstitial cells (MVICs) obtained during mitral valve repair surgery of a proband.

193 itral regurgitation (MR) were treated with a mitral valve repair system (MVRS) via small left thoraco

194 me in which patients underwent transcatheter mitral valve repair using the Edwards PASCAL TMVr system

195 rea (MVA) is important to guide percutaneous mitral valve repair using the MitraClip system.

196 cic Surgeons predicted risk of mortality for mitral valve repair was 4.8% (2.1-9.0) and 6.8% (2.9-10.

197 ents commercially treated with transcatheter mitral valve repair were analyzed.

198 Transcatheter mitral valve repair with a MitraClip device is also prod

199 ry determination who underwent transcatheter mitral valve repair with the MitraClip device in multice

200 tery bypass graft, aortic valve replacement, mitral valve repair) using an interrupted time series mo

201 st- atrial fibrillation ablation or surgical mitral valve repair).

202 Transcatheter mitral valve repair, particularly edge-to-edge leaflet r

203 egurgitation, the most common indication for mitral valve repair.

204 ients with severe MR even after percutaneous mitral valve repair.

205 scharge, 30 days, 6 months, and 1 year after mitral valve repair.

206 uld be considered an alternative to surgical mitral valve repair.

207 oved LV ejection fraction after percutaneous mitral valve repair.

208 height >/=5 mm) and 5 others (8%) underwent mitral valve repair.

209 ral regurgitation to CABG alone or CABG plus mitral-valve repair (combined procedure).

210 l per square meter of body-surface area with mitral-valve repair and 60.6+/-39.0 ml per square meter

211 at 12 months between patients who underwent mitral-valve repair and those who underwent mitral-valve

212 gurgitation undergoing CABG, the addition of mitral-valve repair did not lead to significant differen

213 bypass grafting (CABG) alone with CABG plus mitral-valve repair in patients with moderate ischemic m

214 hemic mitral regurgitation to undergo either mitral-valve repair or chordal-sparing replacement in or

215 In patients undergoing mitral-valve repair or replacement for severe ischemic m

216 We randomly assigned 251 patients to mitral-valve repair or replacement.

217 Mitral-valve repair provided a more durable correction o

218 chemic mitral regurgitation, the addition of mitral-valve repair to CABG did not result in a higher d

219 a clinically meaningful advantage of adding mitral-valve repair to CABG.

220 derate regurgitation, the benefits of adding mitral-valve repair to coronary-artery bypass grafting (

221 The addition of mitral-valve repair was associated with a longer bypass

222 Concomitant mitral-valve repair was associated with a reduced preval

223 Mitral-valve repair was associated with a reduced preval

224 In a randomized trial comparing mitral-valve repair with mitral-valve replacement in pat

225 % in the CABG-alone group (hazard ratio with mitral-valve repair, 0.90; 95% confidence interval, 0.38

226 Limited data exist regarding transcatheter mitral valve replacement (TMVR) for patients with failed

227 More recently, transcatheter mitral valve replacement (TMVR) has emerged as a potenti

228 Transcatheter mitral valve replacement (TMVR) is a potential therapy f

229 Transcatheter mitral valve replacement (TMVR) may be an option for sel

230 e are scarce data available on transcatheter mitral valve replacement (TMVR), and these have been lim

231 replacement (TMVR) for patients with failed mitral valve replacement and repair.

232 50-69 years) who underwent primary, isolated mitral valve replacement in New York State hospitals fro

233 mong patients aged 50 to 69 years undergoing mitral valve replacement in New York State, there was no

234 Transcatheter mitral valve replacement is still in early development.

235 though these findings suggest bioprosthetic mitral valve replacement may be a reasonable alternative

236 cedures were high risk, with an STS PROM for mitral valve replacement of 11%.

237 , 0.90 (0.86-0.93) compared to dysfunctional mitral valve replacement or repair, 0.78 (0.70-0.90), P

238 t, 0.78 (0.73-0.87), P < .001, as did normal mitral valve replacement or repair, 0.90 (0.86-0.93) com

239 85 (74-96) seconds compared to dysfunctional mitral valve replacement or repair, 143 (128-192) second

240 ement, 36 patients with normally functioning mitral valve replacement or repair, 19 patients with dys

241 , P < .001, and also in normally functioning mitral valve replacement or repair, 85 (74-96) seconds c

242 nt or repair, 19 patients with dysfunctional mitral valve replacement or repair, and 31 patients with

243 ormance of the Twelve Intrepid Transcatheter Mitral Valve Replacement System in High Risk Patients wi

244 Mean time from mitral valve replacement to percutaneous PVL repair was

245 for elective isolated or combined aortic and mitral valve replacement were included.

246 ally in the forthcoming era of transcatheter mitral valve replacement.

247 rwent mechanical prosthetic vs bioprosthetic mitral valve replacement.

248 Bioprosthetic vs mechanical prosthetic mitral valve replacement.

249 tnatal intervention; 42% underwent aortic or mitral valve replacement.

250 oup at high or extreme risk for conventional mitral valve replacement.

251 r was 4.8% (2.1-9.0) and 6.8% (2.9-10.1) for mitral valve replacement.

252 air and 60.6+/-39.0 ml per square meter with mitral-valve replacement (mean changes from baseline, -9

253 il 70 years of age among patients undergoing mitral-valve replacement and until 55 years of age among

254 zed trial comparing mitral-valve repair with mitral-valve replacement in patients with severe ischemi

255 nderwent primary aortic-valve replacement or mitral-valve replacement with a mechanical or biologic p

256 In patients undergoing aortic-valve or mitral-valve replacement, either a mechanical or biologi

257 increased substantially for aortic-valve and mitral-valve replacement, from 11.5% to 51.6% for aortic

258 Among patients who underwent mitral-valve replacement, receipt of a biologic prosthes

259 mitral-valve repair and those who underwent mitral-valve replacement.

260 alve replacement and from 16.8% to 53.7% for mitral-valve replacement.

261 e replacements and in 14 of 19 dysfunctional mitral valve replacements or repairs (P < .001 for both)

262 tic valve replacements and in 2 of 36 normal mitral valve replacements or repairs but were abnormal i

263 mic cause of systolic anterior motion of the mitral valve (SAM) is unresolved.

264 Left-sided structures, namely aortic and mitral valve sizes and left ventricular volume, were sig

265 lly important mitral valve regurgitation and mitral valve stenosis.

266 Diastolic mitral valve surface area was quantified by 3-dimensiona

267 ation with the development of indication for mitral valve surgery (0.83).

268 ventricular ejection fraction, who underwent mitral valve surgery (92% repair) at our center between

269 re associated with higher mortality, whereas mitral valve surgery (HR: 0.82) was associated with impr

270 mitral regurgitation in the 24 hours before mitral valve surgery and 13 age- and sex-matched healthy

271 and revascularization when appropriate, and mitral valve surgery and transcatheter interventions.

272 on, surgical ventricular reconstruction, and mitral valve surgery in this high-risk patient populatio

273 Mitral valve surgery is also challenging in these patien

274 The decision to undergo mitral valve surgery is often made on the basis of echoc

275 the most common valvular heart disease, and mitral valve surgery is the gold standard therapy for se

276 re to recognize the importance of FTR during mitral valve surgery may result in inferior early and la

277 CABG with or without mitral valve surgery was associated with lower mortality

278 Prophylactic aortic root replacement and mitral valve surgery were rare during childhood versus a

279 ad electrophysiological studies for AT after mitral valve surgery, 20 patients had prior superior tra

280 rty-eight patients subsequently had isolated mitral valve surgery, and 26 of these had an additional

281 Perioperative bleeding, aortic and mitral valve surgery, and septal surgery increased the o

282 ventricular ejection fraction who underwent mitral valve surgery, brain natriuretic peptide and LV-G

283 y artery bypass graft, aortic valve surgery, mitral valve surgery, or combined procedures.

284 ricular (LV) ejection fraction who underwent mitral valve surgery, we sought to discover whether base

285 41%) either died or developed indication for mitral valve surgery.

286 artile range: 1 to 15 months), 65% underwent mitral valve surgery.

287 urgitation and is the leading indication for mitral valve surgery.

288 Such patients benefit from mitral valve surgery.

289 llation will be ablated at the time of their mitral valve surgery.

290 arranting close follow-up and perhaps, early mitral valve surgery.

291 addition of atrial fibrillation ablation to mitral-valve surgery significantly increased the rate of

292 persistent atrial fibrillation who required mitral-valve surgery to undergo either surgical ablation

293 Among patients undergoing mitral-valve surgery, 30 to 50% present with atrial fibr

294 (Early Feasibility Study of the Tendyne Mitral Valve System [Global Feasibility Study]; NCT02321

295 ed for morphofunctional abnormalities of the mitral valve that could explain a regional mechanical my

296 Following surgical repair of the mitral valve, the dyspnea and palpitations resolved.

297 though systolic anterior motion (SAM) of the mitral valve was discovered as the cause of LV outflow t

298 Recently, percutaneous repair of the mitral valve with a particular device (MitraClip, Abbott

299 Myxomatous mitral valve with prolapse are classically seen with abn

300 equent echocardiography revealing myxomatous mitral valve with prolapse.